BeOne Medicines Ltd. (ONC) exhibits 87.5% gross margins and 10.5% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 63.9x enterprise multiple and 6.8% implied options volatility.
Sustained 87.5% gross profitability converts into 8.4% operating margin and 10.5% ROIC, outpacing sector cost of capital.
ROIC: 10.5% // GM: 87.5%YoY revenue trajectory of +40.2% paired with 2.23% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +40.2% // FCF YLD: 2.23%Altman Z-Score of 6.68 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.68 // F-SCORE: 9/9Trading at 147.2x trailing P/E (123.6x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 147.2x // EV/EBITDA: 63.9xOptions market prices a ±6.8% implied move with a 0.95 put/call ratio around $364.00 max pain.
IMPL MOVE: ±6.8% // P/C: 0.95Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 5.4% net margins.
NET MARGIN: 5.4% // D/E: 0.22x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ONC & activate live FRED threshold breach alerts.